Healthcare Professional Portal

Click here for prescribing information and adverse event reporting information (hosted externally).
Our Services
PI & AE
Browse all resources

Pulse 365 Virtual Spotlight Sessions

Join us for this MIMS Learning webinar series focusing on chronic insomnia in adults. Access recordings from Pulse 365 Virtual events where Idorsia sponsors educational Spotlight sessions. These 45-minute sessions feature experts discussing insomnia, management of chronic insomnia, and real-life patient experiences with QUVIVIQ™▼ (daridorexant).

Access recordings from Pulse 365 Virtual events where Idorsia sponsors educational spotlight sessions. These 45-minute sessions feature experts discussing insomnia, management of chronic insomnia, and real-life patient experiences with QUVIVIQ™▼ (daridorexant). See below for specific agenda topics.

  • Available for a limited time only

Insomnia in Practice: A 24-hour condition with serious health implications

Available on-demand
X CPD hour

Join Dr David O’Regan, Consultant in Psychiatry and Sleep Medicine, for this Pulse 365 Virtual spotlight session exploring the clinical management of chronic insomnia. This session covers:

  • Understanding chronic insomnia and its impact on patient health
  • Non-pharmacological management approaches
  • NICE-approved pharmacological treatment options
  • Case examples from clinical practice

Speaker

Dr David O'Regan

Consultant in Psychiatry and Sleep Medicine, Guy's and St Thomas' NHS Foundation Trust & Sleep London
Click here to read biography
Watch the replay

Gain access to resources on chronic insomnia

Subscribe to get priority updates  and access to videos, data and patient resources, plus details about us and our offerings.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

Discover how QUVIVIQ™ ▼ (daridorexant) is different to other hypnotics1,2:

Works differently1,2

Is taken differently1,3

Is experienced differently1,4

Learn more
Learn more

Book an appointment

One of our product specialists would be happy to answer your questions.

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

References

1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics. 

2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.

3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed March 2026.

4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.

This information is intended for UK healthcare professionals.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

UK-DA-01143
| Date of preparation: March 2026
Copyright © 2026 Idorsia Pharmaceuticals Ltd

Welcome to the Idorsia UK
Healthcare Professional Portal

This information is intended for UK Healthcare Professionals only.

By entering this site you are confirming that you are a UK Healthcare Professional.

I am a UK healthcare professional
I am a member of the public

UK-DA-00217 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

David earned a first class honours BSc in Physiology from University College Cork (Ireland), followed by a PhD in neuroendocrinology funded by the Wellcome Trust at the University of Edinburgh, before completing his medical degree at the University of Cambridge.

His specialist training in sleep medicine spanned 4 years at University College London Hospitals. Since 2016, he has served as a Consultant in Psychiatry and Sleep Medicine at Guy’s Hospital. He currently holds an Honorary Senior Lectureship with King’s College London and a MRCPsych Lectureship with University College London.

David recently completed his term as President of the Royal Society of Medicine’s Sleep Medicine Section. He remains deeply engaged in research, contributing extensively to sleep medicine literature. He pioneered the development of the first group-based talking therapy designed for NREM Parasomnias.

As an established expert in insomnia, David participates as a panel member in various international initiatives, among them Redefining Education on Sleep Therapy.

Welcome back!

Please complete the form below to sign in.

You don’t have an account? 

Sign up

You are now leaving
pro.idorsia.uk

You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)

Continue to medicines.org.uk

UK-DA-00439 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Your resource is ready to download.

Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.

Download will open in a new window.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

You are now leaving
pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.

You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.

Cancel
Go to link

UK-DA-00445 | Date of preparation: Februrary 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.

It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.

For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.

Create an account
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

Select below to keep informed of further resources:

You already have an account? 

Sign in

Gain access to resources on chronic insomnia​

Register to get access to:

  • Insightful videos
  • Patient resources
  • E-Learning programme
  • And details about us and our offerings